



Calculating daily dose in the OMOP CDM

Theresa Burkard, PhD Health Data Science Group – University of Oxford, UK

OHDSI Community Call June 24, 2024

Kim López-Güell, Artem Gorbachev, Lucía Bellas, Annika M Jödicke, Edward Burn, Maria de Ridder, Mees Mosseveld, Jasmine Gratton, Sarah Seager, Dina Vojinovic, Miguel A. Mayer, Angela Leis Machín, Juan Manuel Ramírez-Anguita, Marek Oja, Raivo Kolde, Klaus Bonadt, Daniel Prieto-Alhambra, Chistian Reich & Martí Català





ORIGINAL ARTICLE





Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model

| Theresa Burkard Kim López-Güell Artem Gorbachev Lucía Bellas |
|--|
| Annika M. Jödicke Edward Burn Maria de Ridder Mees Mosseveld |
| Jasmine Gratton ⁵ Sarah Seager ⁵ Dina Vojinovic ⁶ Miguel Angel Mayer ^{7,8} |
| Juan Manuel Ramírez-Anguita ^{8,9} Angela Leis Machín ⁸ Marek Oja ¹⁰ |
| Raivo Kolde 10 Klaus Bonadt 11 Daniel Prieto-Alhambra 1,4 0 Chistian Reich 2 |
| Martí Català 1 |

Correspondence

Daniel Prieto-Alhambra, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Windmill Road, OX37LD, Oxford, UK.

Email: daniel.prietoalhambra@ndorms.ox.ac.uk

Funding information

Darwin EU, Grant/Award Number: EMA/ 2021/08/TDA; EHDEN

Abstract

Purpose: We aimed to develop a standardized method to calculate daily dose (i.e., the amount of drug a patient was exposed to per day) of any drug on a global scale using only drug information of typical observational data in the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) and a single reference table from Observational Health Data Sciences And Informatics (OHDSI).

Materials and Methods: The OMOP DRUG_STRENGTH reference table contains information on the strength or concentration of drugs, whereas the OMOP DRUG_EXPOSURE table contains information on patients' drug prescriptions or dispensa-





¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK

²Odysseus Data Services, Cambridge, Massachusetts, USA

³Clinical Pharmacology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain

⁴Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

⁵IQVIA Ltd, London, UK

⁶IQVIA Solutions B.V, Amsterdam, the Netherlands

⁷Management and Control Department, Hospital del Mar Barcelona, Barcelona, Spain

⁸Research Program on Biomedical Informatics (GRIB). Hospital del Mar Research Institute (IMIM), Barcelona, Spain

⁹Universitat Pompeu Fabra, Barcelona, Spain

¹⁰Institute of Computer Science, University of Tartu, Tartu, Estonia

¹¹IQVIA Commercial GmbH & Co. OHG, Frankfurt, Germany

Background









DRUG_STRENGTH + DRUG_EXPOSURE => DOSE



Methods



DRUG_STRENGTH

| Drug_ | Amount | Amount_unit_ | Numerator | Numerator_ | Denominator | Denominator_ |
|----------|------------------|-------------------|-------------------|-------------------|-----------------|-------------------|
| concept_ | _value | concept_id | _value | unit_concept | _value | unit_concept_id |
| id | | | | _id | | |
| 19023311 | <mark>200</mark> | <mark>8576</mark> | NA | NA | NA | NA |
| 1139060 | NA | NA | <mark>6000</mark> | <mark>8576</mark> | <mark>30</mark> | <mark>8587</mark> |
| 19125241 | NA | NA | <mark>100</mark> | <mark>8576</mark> | <mark>NA</mark> | <mark>8587</mark> |

Clinically relevant units -> 41 individual patterns





Dose formulas - Overview



TABLE 3 Dose formulas for the three groups of drug strength patterns.

| Pattern group | DRUG_STRENGTH information | Daily dose formula | Usual dose forms |
|------------------------------------|---|---|--|
| Fixed amount formulation patterns | amount_value numeric, amount_unit present, missing numerator_unit, and missing denominator_unit | $\frac{\text{Amount value} \times \text{Quantity}}{(\text{Drug exposure end date} - \text{Drug exposure start date} + 1)^a}$ | Non-divisible dose forms, for example, pills, capsules, suppositories, and patches |
| Time-based formulation patterns | numerator_value numeric, numerator_unit present, and denominator_unit "hour" | Denominator value ≤24 h: Numerator value Denominator value >24 h or missing denominator value (i.e., denominator value = 1): Numerator value × 24 Denominator value | Non-divisible dose forms particularly dosed by time, for example, patches and extended releases solid oral dose forms |
| Concentration formulation patterns | numerator_value numeric, numerator_unit present, and denominator_unit not "hour" | $\frac{\text{Numerator value} \times \text{Quantity}}{(\text{Drug exposure end date} - \text{Drug exposure start date} + 1)^b}$ | Divisible dose forms, for example, oral/inhalable solutions and injectables |

Note: Amount value, numerator value, and denominator value come from the DRUG_STRENGTH table. Quantity, drug exposure start date, and drug exposure end date come from the DRUG_EXPOSURE table. The dose formulas were implemented in the DrugUtilisation R package, ¹⁵ which is freely available under the Apache License (Version 2.0) and can be obtained from CRAN (https://cran.r-project.org/web/packages/DrugUtilisation/index.html). ^aThe quantity is the number of units/tablets/capsules/others prescribed or dispensed.


^bOur clinical assessment suggested that the quantity depended on whether denominator value was missing (=1) or not. In cases where denominator value was missing, the quantity was mainly populated by giving the total volume/weight/others of the product prescribed or dispensed. In cases where the denominator value was not missing, we mainly saw single or multiple unit packages, and the quantity was populated with the number of bottles/units/sachets/others of the product prescribed or dispensed.





Assess coverage and output the daily dose overall, by unit, by unit + route, and by unit + route + drug strength pattern







Check coverage of daily dose computation in a sample of the cdm for selected concept sets and ingredient

Usage

dailyDoseCoverage(cdm, ingredientConceptId)

Arguments

cdm

A cdm reference created using CDMConnector

ingredientConceptId

Code indicating the ingredient of interest

Value

The function returns information of the coverage of computeDailyDose.R for the selected ingredients and concept sets

Results – dose calculation by unit



Table 4. Overall daily dose calculations per ingredient per database

Bold values indicate the results of the larger strata

| | Median daily dose (IQR) | | | | | | |
|------------|-------------------------|---------------------|------------------|-------------|--------------------|----------------------------|--|
| Ingredient | metformin | enoxaparin | furosemide | salmeterol | tiotropium | fentanyl | |
| WHO DDD | 2 g oral | 2000 IU injection | 40 mg | 0.1 mg | 0.01 mg inhalable | 0.6 mg nasal / sublingual, | |
| | | (100 IU = 1 mg) | oral / injection | inhalation | powder, | 1.2 mg transdermal | |
| | | | | | 0.005 mg inhalable | | |
| | | | | | solution | | |
| CPRD | 1700 mg | 60 mg | 40 mg | 0.00 mg | 0.018 mg | 0.6 mg | |
| GOLD | (1000-2000) | (40-120) | (20-40) | (0.00-0.10) | (0.018-0.019) | (0.6-1.2) | |
| IPCI | 1000 mg | 40 mg (22-100), | 40 mg | 0.10 mg | 0.018 mg | 1.4 mg | |
| | (938-2000) | 4000 IU (1521-4000) | (20-40) | (0.10-0.10) | (0.005-0.018) | (0.7-2.8) | |
| MAITT | 1700 mg | 2667 IU | 60 mg | 0.20 mg | 0.010 mg | 0.6 mg | |
| | (1000-2000) | (1333-4000) | (40-60) | (0.10-0.20) | (0.005-0.010) | (0.6-1.2) | |
| P+ | 1000 mg | 160 mg | 40 mg | 6.00 mg | 0.018 mg | 0.1 mg | |
| | (500-2000) | (64-160) | (20-40) | (6.00-6.00) | (0.018-0.020) | (0.1-0.2) | |
| IQVIA DA | 2000 mg | 27 mg (20-40), | 40 mg | 0.15 mg | 0.018 mg | 0.3 mg | |
| | (1500-2000) | 2.7 IU (1.3-4) | (40-40) | (0.15-0.15) | (0.015-0.054) | (0.1-0.6) | |
| IQVIA LPD | 1000 mg | 8000 IU | 40 mg | 0.04 mg | 0.54 mg | NA | |
| | (850-1700) | (4000-16'000) | (40-40) | (0.04-0.17) | (0.018-0.54) | | |
| IMASIS | 850 mg | 60 mg | 40 mg | 0.04 mg | 0.54 mg | 5 mg | |
| | (425-850) | (20-60) | (40-40) | (0.04-3.00) | (0.54 - 0.054) | (0.6-7.5) | |

CPRD GOLD: Clinical Practice Research Datalink GOLD; DA: Disease Analyzer; IMASIS: Multicenter Integrated Hospital Information System; IPCI: Integrated Primary Care Information; LPD: Longitudinal Patient; MAITT: University of Tartu dataset of health data; NA: not available; P+: PharMetrics@Plus for Academics





Tiotropium daily dose stratified by unit + route + drug strength pattern



all by inhalation

Drug strength: 0.018 mcg

Table 5. Daily dose calculations of tiotropium (WHO DDD: 0.01 mg inhalable powder / 0.005 mg inhalable solution) stratified by route, and by pattern and route

| | Add | itional stratifi | cation by pattern |
|-------------|--------------------------|------------------|----------------------------|
| | Stratum | % | Daily dose median (IQR) |
| CPRD | fixed_amount_mg | 86.1 | 0.018 mg (0.018-0.019) |
| GOLD | mg_per_missing_actuation | 13.9 | 0.005 mg (0.005-0.005) |
| IPCI | fixed_amount_mg | 60.7 | 0.018 mg (0.018-0.018) |
| | mg_per_actuation | 39.3 | 0.005 mg (0.005-0.005) |
| | mg_per_missing_actuation | 0.0 | 0.000 mg (0.000-0.003) |
| | NA | 0 | |
| MAITT | mg_per_missing_actuation | 100 | 0.010 mg (0.005-0.010) |
| P+ | fixed_amount_mg | 51.7 | 0.018 mg (0.018-0.018) |
| | mg_per_actuation | 48.3 | 0.020 mg (0.020-0.020) |
| IQVIA DA | fixed_amount_mg | 58.4 | 0.036 mg (0.018-0.054) |
| DA | mg_per_actuation | 20.7 | 0.010 mg (0.005-0.015) |
| | mg_per_ml | 7.8 | 0.000 mg (0.000-0.000) |
| | NA | 13.0 | |
| IQVIA | fixed_amount_mg | 69.2 | 0.540 mg (0.036-0.540) |
| LPD | mg_per_actuation | 30.8 | 0.005 mg (0.003-0.45) |
| IMASIS | mg_per_actuation | 31.8 | 0.540 mg (0.540-0.054) |
| | NA | 68.3 | |





Tiotropium daily dose stratified by unit + route + drug strength pattern



Drug strength: 0.018 mcg

Table 5. Daily dose calculations of tiotropium (WHO DDD: 0.01 mg inhalable powder / 0.005 mg inhalable solution) stratified by route, and by pattern and route

| | Add | itional stratific | cation by pattern | — all by inhalation |
|--------|--------------------------|-------------------|----------------------------|-------------------------|
| | Stratum | % | Daily dose median (IQR) | an by initialiation |
| CPRD | fixed_amount_mg | 86.1 | 0.018 mg (0.018-0.019) | Inhalable powder |
| GOLD | mg_per_missing_actuation | 13.9 | 0.005 mg (0.005-0.005) | Inhalable solution |
| IPCI | fixed_amount_mg | 60.7 | 0.018 mg (0.018-0.018) | Inhalable powder |
| | mg_per_actuation | 39.3 | 0.005 mg (0.005-0.005) | Inhalable solution |
| | mg_per_missing_actuation | 0.0 | 0.000 mg (0.000-0.003) | |
| | NA | 0 | | |
| MAITT | mg_per_missing_actuation | 100 | 0.010 mg (0.005-0.010) | Inhalable solution |
| P+ | fixed_amount_mg | 51.7 | 0.018 mg (0.018-0.018) | Inhalable powder |
| | mg_per_actuation | 48.3 | 0.020 mg (0.020-0.020) | Inhalable solution |
| IQVIA | fixed_amount_mg | 58.4 | 0.036 mg (0.018-0.054) | Inhalable powder |
| DA | mg_per_actuation | 20.7 | 0.010 mg (0.005-0.015) | Inhalable solution |
| | mg_per_ml | 7.8 | 0.000 mg (0.000-0.000) | |
| | NA | 13.0 | | |
| IQVIA | fixed_amount_mg | 69.2 | 0.540 mg (0.036-0.540) | |
| LPD | mg_per_actuation | 30.8 | 0.005 mg (0.003-0.45) | Inhalable solution |
| IMASIS | mg_per_actuation | 31.8 | 0.540 mg (0.540-0.054) | |
| | NA | 68.3 | | BOTNAR KENNEDY |

Fentanyl daily dose stratified by unit + route + drug strength pattern



Table 6. Daily dose calculations of fentanyl (WHO DDD: 0.6 mg nasal / sublingual, 1.2 mg transdermal) stratified by route and unit, and by pattern and route

| | Stratification by route | | | Additional stratif | Additional stratification by pattern | | |
|-------|-------------------------|------|----------------------------|--------------------------|--------------------------------------|----------------------------|--|
| | Stratum | % | Daily dose median (IQR) | Stratum | % | Daily dose median (IQR) | |
| IQVIA | transdermal | 96.2 | 0.3 mg (0.1-0.6) | mg_per_h | 51.0 | 0.0 mg (0.0-0.1) | |
| DA | | | | mg_per_missing_h | 46.0 | 0.6 mg (0.3-1.2) | |
| | | | | fixed_amount_mg | 0.0 | 0.0 mg (0.0-0.0) | |
| | buc./subl. | 3.4 | 0.3 mg (0.2-0.9) | fixed_amount_mg | 3.4 | 0.3 mg (0.2-0.9) | |
| | nasal | 0.4 | 0.1 mg (0.0-0.2) | mg_per_ml | 0.3 | 0.0 mg (0.0-0.2) | |
| | | | | mg_per_missing_actuation | 0.0 | 0.2 mg (0.2-0.2) | |
| | | | | mg_per_missing_ml | 0.0 | 0.0 mg (0.0-0.0) | |
| | injection | 0.1 | 0.0 mg (0.0-0.2) | mg_per_ml | 0.1 | 0.0 mg (0.0-0.2) | |
| | oral | 0.0 | 1.5 mg (0.3-1.5) | fixed_amount_mg | 0.0 | 1.5 mg (0.3-1.5) | |
| | NA | 0.0 | | NA | 0.0 | | |
| | | | | | | | |





Fentanyl daily dose stratified by unit + route + drug strength pattern



Table 6. Daily dose calculations of fentanyl (WHO DDD: 0.6 mg nasal / sublingual, 1.2 mg transdermal) stratified by route and unit, and by pattern and route

| | Stratification by route | | | Additional strati | Additional stratification by pattern | | |
|-------|-------------------------|------|----------------------------|--------------------------|--------------------------------------|----------------------------|--|
| | Stratum | % | Daily dose median (IQR) | Stratum | % | Daily dose median (IQR) | |
| IQVIA | transdermal | 96.2 | 0.3 mg (0.1-0.6) 🚄 | mg_per_h | 51.0 | 0.0 mg (0.0-0.1) | |
| DA | | | | mg_per_missing_h | 46.0 | 0.6 mg (0.3-1.2) | |
| | | | | fixed_amount_mg | 0.0 | 0.0 mg (0.0-0.0) | |
| | buc <u>/subl</u> . | 3.4 | 0.3 mg (0.2-0.9) | fixed_amount_mg | 3.4 | 0.3 mg (0.2-0.9) | |
| | nasal | 0.4 | 0.1 mg (0.0-0.2) 🚄 | mg_per_ml | 0.3 | 0.0 mg (0.0-0.2) | |
| | | | | mg_per_missing_actuation | 0.0 | 0.2 mg (0.2-0.2) | |
| | | | | mg_per_missing_ml | 0.0 | 0.0 mg (0.0-0.0) | |
| | injection | 0.1 | 0.0 mg (0.0-0.2) | mg_per_ml | 0.1 | 0.0 mg (0.0-0.2) | |
| | oral | 0.0 | 1.5 mg (0.3-1.5) | fixed_amount_mg | 0.0 | 1.5 mg (0.3-1.5) | |
| | NA | 0.0 | | NA | 0.0 | | |
| | | | | | | | |





Fentanyl daily dose stratified by unit + route + drug strength pattern



Table 6. Daily dose calculations of fentanyl (WHO DDD: 0.6 mg nasal / sublingual, 1.2 mg transdermal) stratified by route and unit, and by pattern and route

| | Stratification by route | | | Additional strati | Additional stratification by pattern | | |
|-------|-------------------------|------|----------------------------|--------------------------|--------------------------------------|----------------------------|--|
| | Stratum | % | Daily dose median (IQR) | Stratum | % | Daily dose median (IQR) | |
| IQVIA | transdermal | 96.2 | 0.3 mg (0.1-0.6) | mg_per_h | 51.0 | 0.0 mg (0.0-0.1) | |
| DA | | | | mg_per_missing_h | 46.0 | 0.6 mg (0.3-1.2) | |
| | | | | fixed_amount_mg | 0.0 | 0.0 mg (0.0-0.0) | |
| | buc <u>/subl</u> . | 3.4 | 0.3 mg (0.2-0.9) | fixed_amount_mg | 3.4 | 0.3 mg (0.2-0.9) | |
| | nasal | 0.4 | 0.1 mg (0.0-0.2) | mg_per_ml | 0.3 | 0.0 mg (0.0-0.2) | |
| | | | | mg_per_missing_actuation | 0.0 | 0.2 mg (0.2-0.2) | |
| | | | | mg_per_missing_ml | 0.0 | 0.0 mg (0.0-0.0) | |
| | injection | 0.1 | 0.0 mg (0.0-0.2) | mg_per_ml | 0.1 | 0.0 mg (0.0-0.2) | |
| | oral | 0.0 | 1.5 mg (0.3-1.5) | fixed_amount_mg | 0.0 | 1.5 mg (0.3-1.5) | |
| | NA | 0.0 | | NA | 0.0 | | |
| | | | | | | | |





Strengths / limitations





Systematic and structured approach

Stratification by route and drug strength pattern (often aligns with formulation)

Dose formulas benchmarked against international standards

Implementation in an R package



Sig would be more precise but not resolved into a standard representation yet

Ingredients and databases may not be totally representative of the entire OMOP spectrum

No standard harmonization of IU and mg





Conclusion



We provided a standardised methodology for calculating daily doses in OMOP CDM

The suggested dose formulas enhance the reliability, transparency, and reproducibility of daily dose calculation in OMOP CDM





THANK YOU!







Pharmaco- and Device epidemiology Group Prof. Prieto-Alhambra



Artem Gorbatchev Lucia Bellas





